Tiziana Life Sciences Ltd (0RP.SG)
| Previous close | 0.9750 |
| Open | 0.9900 |
| Bid | 0.9750 x N/A |
| Ask | 1.0200 x N/A |
| Day's range | 0.9900 - 0.9900 |
| 52-week range | 0.4860 - 1.2800 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Tiziana Life Sciences Ltd's (NASDAQ:TLSA) market cap rose US$30m last week; retail investors who hold 51% profited and so did insiders
Key Insights Tiziana Life Sciences' significant retail investors ownership suggests that the key decisions are...
- GlobeNewswire
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMSFirst Phase 2 trial employing intranasal foralumab for treating inflammatory neurological diseaseTiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with non-active SPMSPhase 2 protocol to be submitted to the FDA in AprilPhase 2 clinical trial expected to start in Q3 2023 NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiz
- GlobeNewswire
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its Chairman and Acting Chief Executive Officer, purchased 8,000 common shares at $0.89 per share, bringing his total holding to 38,701,237 common shares. About ForalumabActivated T cells play an important role in the inf
